Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Language
Publication year range
1.
Braz. J. Pharm. Sci. (Online) ; 58: e18887, 2022. tab, graf
Article in English | LILACS | ID: biblio-1420484

ABSTRACT

Abstract A series of Trolox amide derivatives were synthesized by modifying the carboxyl groups of Trolox. Thirty target compounds were obtained and characterized through nuclear magnetic resonance and mass spectrometry. Trolox derivatives were employed to explore the potential structure-antioxidant activity relationships. The antioxidant activities of these compounds were evaluated using 1,1-diphenyl-2-picrylhydrazyl (DPPH), 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), ferric reducing antioxidant power (FRAP) and hydroxyl radical assays. DPPH scavenging activity test results illustrated that compounds exhibited scavenging activities similar to L-ascorbic acid and Trolox, with compounds 14a, 18a, 24a and 26a in particular exhibiting higher scavenging activities than L-ascorbic acid. The results demonstrated that compounds displayed ABTS scavenging activities similar to L-ascorbic acid and Trolox, with compounds 26a and 29a in particular having potency twofold higher. FRAP assay results indicated that compounds 11a, 19a, 25a, 29a and 30a had activity similar to Trolox. The results revealed that compounds 6a and 19a had similarly high hydroxyl radical-scavenging activities as Trolox. The results of α-glucosidase experiments uncovered that compounds 10a, 25a, 28a and 29a had excellent inhibitory activity, which was similar to that of acarbose and different from Trolox. The results of acetylcholinesterase and butyrylcholinesterase experiments demonstrated that some compounds had weak anticholinesterase activities. 26a and 29a are important Trolox derivatives with better biological activity profiles and deserve further study


Subject(s)
Biological Products/analysis , Mass Spectrometry/methods , Magnetic Resonance Spectroscopy/methods , Cholinesterase Inhibitors/adverse effects , Acarbose/adverse effects , Amides/agonists , Antioxidants/analysis
2.
Biomed Res Int ; 2018: 4567019, 2018.
Article in English | MEDLINE | ID: mdl-30225254

ABSTRACT

The synthesis of new substituted arylphosphoramidates is performed in two steps through phosphorylation of the corresponding alcohols followed by aminolysis. The formation of the desired phosphoramidates depends on the subsequent addition of the two alcohols with the amine being added at the last step. The products were obtained in 58-95% yields. They were characterized mainly by multinuclear (1H, 13C, 31P, and 19F) NMR and IR spectroscopy. In addition, the antimicrobial and antiacetylcholinesterase activities were evaluated. The results showed acetylcholinesterase activity by some compounds, whilst no significant inhibitory effect against the tested bacterial strains has been recorded.


Subject(s)
Amides/pharmacology , Anti-Bacterial Agents/pharmacology , Phosphoric Acids/pharmacology , Alcohols , Amides/agonists , Anti-Infective Agents , Bacteria , Microbial Sensitivity Tests , Phosphoric Acids/agonists , Structure-Activity Relationship
3.
Can J Physiol Pharmacol ; 87(8): 595-601, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19767883

ABSTRACT

Radial artery (RA) vasospasm remains a potential cause of early graft failure after coronary artery bypass graft surgery, despite pretreatment with alpha-adrenergic or calcium channel blockers. Our aim was to investigate the mechanism of the vasorelaxant effects of Rho-kinase inhibitors (Y-27632 and fasudil) on the human RA. Segments were obtained from 30 patients undergoing coronary artery bypass graft and were divided into 3-4 mm vascular rings. The rings were stimulated with 10(-5) mol/L phenylephrine (PE) by using the isolated tissue bath technique and were relaxed with 10(-6) mol/L acetylcholine. Relaxation responses were recorded for Y-27632 (10(-9)-10(-4) mol/L), fasudil (10(-9)-10(-4) mol/L), and sodium nitroprusside (SNP) (10(-9)-10(-5) mol/L). Y-27632 and fasudil relaxation responses were repeated in either N(G)-nitro-L-arginine (L-NNA), which is a specific endothelial nitric oxide synthase inhibitor, or 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), which is a guanylate cyclase inhibitor. SNP relaxation responses were repeated in 10(-8) mol/L Y-27632 and 10(-8) mol/L fasudil. Y-27632 and fasudil caused concentration-dependent vasorelaxation in RA rings precontracted with PE, and maximal relaxation (100%) was recorded at the highest concentration used (10(-4) mol/L). The vasorelaxant effects of Y-27632 and fasudil were significantly reduced in the presence of L-NNA and ODQ, and the pD2 values of Y-27632 and fasudil were not changed. The vasorelaxant effects of SNP were significantly increased in the presence of Y-27632 and fasudil, and the pD(2) values of SNP were not changed. These findings indicate that Y-27632 and fasudil caused concentration-dependent vasorelaxation in the RA rings. Because this effect was decreased in a dose-dependent manner by L-NNA and ODQ, the relaxant effects of Y-27632 and fasudil could be due to stimulation by nitric oxide that is being released. Rho-kinase inhibitors may have an important role in preventing vasospasm in arterial grafts used for coronary artery surgery.


Subject(s)
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/analogs & derivatives , Amides/pharmacology , Protein Kinase Inhibitors/agonists , Protein Kinase Inhibitors/pharmacology , Pyridines/pharmacology , Radial Artery/drug effects , Vasoconstriction/drug effects , rho-Associated Kinases/antagonists & inhibitors , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/agonists , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/pharmacology , Aged , Amides/agonists , Constriction, Pathologic/enzymology , Constriction, Pathologic/prevention & control , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Nitroarginine/pharmacology , Nitroprusside/pharmacology , Oxadiazoles/pharmacology , Pyridines/agonists , Quinoxalines/pharmacology , Radial Artery/enzymology , Receptors, Calcium-Sensing/agonists , Receptors, Calcium-Sensing/physiology , Vasoconstriction/physiology , Vasodilation/drug effects , Vasodilation/physiology , rho-Associated Kinases/physiology
4.
Eur J Pharmacol ; 610(1-3): 68-74, 2009 May 21.
Article in English | MEDLINE | ID: mdl-19289115

ABSTRACT

Our purposes were to perform the pharmacological characterization of PGF(2alpha) receptor (prostanoid FP-receptor) involved in human umbilical vein contraction and confirm its expression in this tissue. Umbilical cords from healthy patients after full-term deliveries were employed. The vein was dissected out of cords and used for either isolated organ bath or reverse transcription-polymerase chain reaction (RT-PCR) and Western blot assays. The natural prostanoid FP-receptor agonist, PGF(2alpha), and its selective analogues, latanoprost and bimatoprost free acids are full agonists (produce more than 80% of the maximal contractile response to 5-HT) in human umbilical vein. The agonist potency (pEC(50)) order was PGF(2alpha) (6.01+/-0.05)>latanoprost free acid (5.65+/-0.07)=bimatoprost free acid (5.59+/-0.08). The contractile effects of PGF(2alpha) and latanoprost free acid were blocked competitively by the prostanoid FP-receptor antagonist, AL-8810. The antagonist potencies (pK(B)) of AL-8810 vs. PGF(2alpha) (5.93+/-0.05) and vs. latanoprost free acid (6.40+/-0.08) in human umbilical vein are in good agreement with its ability to antagonize prostanoid FP receptors of rat, mouse and human cells. In all samples, clear signal was detected for cDNA amplification of prostanoid FP receptor and the specific prostanoid FP-receptor antibody recognized a protein of approximately 64 kDa. In conclusion, taking into account the obtained functional and biochemical data, we propose for the first time that human umbilical vein express prostanoid FP-receptors and these receptors could be involved in the vasoconstriction action of PGF(2alpha) in this tissue.


Subject(s)
Receptors, Prostaglandin/metabolism , Umbilical Veins/drug effects , Vasoconstriction/drug effects , Vasoconstrictor Agents/pharmacology , Amides/agonists , Bimatoprost , Cloprostenol/agonists , Cloprostenol/analogs & derivatives , Dinoprost/agonists , Dose-Response Relationship, Drug , Endothelium, Vascular/metabolism , Gene Expression/drug effects , Humans , Infant, Newborn , Latanoprost , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Prostaglandins F, Synthetic/agonists , Receptors, Prostaglandin/agonists , Umbilical Veins/cytology , Umbilical Veins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...